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a b s t r a c t 
Short-term increases in oxidative stress and decreases in motor function, including debilitating effects on 
balance and motor control, can occur following primary mild traumatic brain injuries (mTBI). However, the 
long-term effects on motor unit impairment and integrity as well as the molecular mechanisms underlying 
secondary injuries are poorly understood. We hypothesized that changes in central nervous system-speciﬁc 
protein (CSP) expression might correlate to these long-term effects. To test our hypothesis, we longitudinally 
assessed a closed-skull mTBI mouse model, vs. sham control, at 1, 7, 30, and 120 days post-injury. Motor
impairment was determined by rotarod and grip strength performance measures, while motor unit integrity 
was determined using electromyography. Relative protein expression was determined by microwave and 
magnetic (M 2 ) proteomics of ipsilateral brain tissue, as previously described. Isoprostane measurements were 
performed to conﬁrm a primary oxidative stress response. Decoding the relative expression of 476 ± 56 
top-ranked proteins for each specimen revealed statistically signiﬁcant changes in the expression of two 
well-known CSPs at 1, 7 and 30 days post-injury: P < 0.001 for myelin basic protein (MBP) and p < 0.05 for
myelin associated glycoprotein (MAG). This was conﬁrmed by Western blot. Moreover, MAG, αII-spectrin 
(SPNA2) and neuroﬁlament light (NEFL) expression at 30 days post-injury were directly related to grip 
strength ( p < 0.05). While higher-powered studies of larger cohorts merit further investigation, this study 
supports the proof-of-concept that M 2 proteomics is a rapid method to quantify putative protein biomarkers 
and therapeutic targets of mTBI and suggests the feasibility of CSP expression correlations to long-term 
effects on motor impairment. 
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ttp://dx.doi.org/10.1016/j.trprot.2014.03.002 1. Introduction 
Traumatic brain injury (TBI) is caused by sudden and violent 
trauma, including: vehicle accidents, falls, sport related injuries, and 
acts of violence such as those occurring in combat situations. The CDC 
has recently reported that nearly one third (30.5%) of deaths associ- 
ated with injury include a diagnosis of TBI and there are an estimated 
5.3 million U.S. residents living with TBI-related disabilities [ 1 ]. Eco- 
nomic costs resulting from TBI were estimated at $76.5 billion for 
2010, including $11.5 billion for direct medical costs and $64.8 billion 
for indirect costs (e.g., lost wages, lost productivity, and nonmedical 
expenditures) [ 2 , 3 ]. TBI has been described as the “signature” injury of 
veterans from the conﬂicts in Iraq and Afghanistan, where repetitive en access article under the CC BY license ( http: // creativecommons.org / licenses / by / 
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 and multiple combat injures are common [ 4 ]. Consequently, the DOD
alone has invested more than $374.9 million to increase the qual-
ity and access to care for these veterans [ 5 ]. Approximately 20% of
the 1,348,405 citizens that were deployed since September 11, 2001,
were diagnosed with TBI, where 82% of these injuries were considered
mild (mTBI) [ 5 ]. 
The devastating physical and emotional effects of TBI are com-
pounded by a lack of FDA-approved diagnostic, prognostic or predic-
tive biomarkers. The acute effects of TBI (primary injuries) have been
the focus of most biomarker studies, while sub-acute and long-term
effects of TBI (secondary injuries) have not been received as much
attention. Secondary injuries due to mTBI are expected to be par-
ticularly subtle at the molecular level, posing a profound challenge
for the discovery of clinically relevant biomarkers. Primary injuries
are characterized by short-term increases in oxidative stress and de-
creases in motor function [ 6 –9 ]. These initial events are followed
by a poorly understood secondary response characterized by long-
term effects associated with neuronal degeneration and functional
and cognitive deﬁcits, including deﬁcits in memory, coordination,
judgment, balance and ﬁne motor skills [ 7 ]. While the importance of
investigating these long-term changes is becoming more appreciated
due to strengthening links between TBI and multiple age-associated
neurodegenerative diseases [ 10 –15 ], few pre-clinical studies have ex-
amined the long-term functional and biochemical changes associated
with mTBI [ 11 , 16 –19 ]. 
The most sensitive (most true-positive) and speciﬁc (least false-
positive) biomarkers are expected to be proteins. More than 24,000
genes are translated into an estimated 2 million protein isoforms in
humans, encoding far more molecular diversity than the relatively
static genome or transcriptome. Paradoxically, less than 100 proteins
are routinely quantiﬁed in blood today [ 20 , 21 ]. Proteins must be mea-
sured directly due to the poor correlation between the transcriptome
and proteome due to alternative splicing, post-translational modiﬁca-
tions, single nucleotide polymorphisms, limiting ribosomes available
for translation, mRNA and protein stability, and other actors (e.g., mi-
croRNA). Central nervous system-speciﬁc proteins (CSPs), transported
across the damaged blood–brain-barrier to cerebral spinal ﬂuid (CSF)
or blood, are attractive protein biomarkers for TBI because they are not
expected at appreciable levels in the circulation of healthy controls.
However, amino acid sequence speciﬁc tandem mass spectrometry
(MS / MS)-based proteomic analysis of low abundance CSPs can be
confounded by masking effects due to high abundance proteins, par-
ticularly in CSF or blood where protein abundance can span up to 12
orders of magnitude. For these reasons and others, proteomic analysis
of CSPs in brain tissue is a sound strategy for prioritizing putative pro-
tein biomarkers for future immunoassay (e.g., ELISA) measurements
in CSF or blood. 
We hypothesized that changes in CSP expression might correlate
to these long-term secondary effects. To test our hypothesis, we longi-
tudinally assessed a closed-skull mTBI mouse model, vs. sham control,
at 1, 7, 30, and 120 days post-injury. Motor impairment was deter-
mined by rotarod and grip strength performance measures, while
motor unit integrity was determined by electromyography. Relative
protein expression was determined by microwave and magnetic (M 2 )
proteomics of brain tissue as previously described [ 22 , 23 ], where con-
ﬁrmation for selected proteins was provided with Western blotting.
Isoprostane measurements were performed to conﬁrm a primary ox-
idative stress response. Decoding the relative protein expression for
each specimen for 476 ± 56 top-ranked proteins revealed statisti-
cally signiﬁcant changes in the expression of two well-known CSPs
at 1, 7 and 30 days post-injury: p < 0.001 for myelin basic protein
(MBP) and p < 0.05 for myelin associated glycoprotein (MAG). This
was conﬁrmed by Western blot. Moreover, MAG, αII-spectrin (SPNA2)
and neuroﬁlament light (NEFL) expression at 30 days post-injury were
signiﬁcantly correlated to grip strength ( p < 0.05). 
 2. Materials and methods 
2.1. Closed-skull impact model 
mTBI was induced at 60 days with the TBI 0310 impact device
(Percision Systems LLC). TBI was administered as a closed cortical in-
jury (CCI) using pneumatic force. The mortality rate was less than 5%;
there were no overt structural abnormalities, intracranial bleeds, or
edema observed with MRI, indicating that TBI severity was mild. Prior
to surgery mice were anesthetized in a chamber with 2–4% isoﬂurane
in 100% oxygen. Anesthesia was maintained at 1% for the remaining
procedures. During surgery the mean arterial pressure was monitored
with a transducer, and mice were ﬁxed to a pad in the prone position
under a heating lamp to maintain body temperature. A midline in-
cision in the scalp was made and the skin and periosteum retracted.
A stainless steel disk (7 mm in diameter and 3 mm thick) was glued
to the skull between the coronal and lambdoid sutures over the so-
matosensory cortex using super glue. TBI was induced using a CCI
device calibrated to deliver a blow at 4.5 m / s, 100 ms dwell time and
a depth of 2 mm directly to the disk. Following injury, the disk and
glue were removed and the incision sutured. Antibiotic ointment was
applied to wounds. Animals were allowed to wake in a warm / dry
cage with a sterile liner and monitored for at least 1 h. Sham animals
were subjected to all procedures except that the impact device was
calibrated to a level just above the disk resulting in no impact. All
animals were observed and weighed daily until completion of exper-
imentation. At selected survival times, mice were anesthetized under
isoﬂurane, sacriﬁced, and brain tissue (and plasma) specimens were
snap frozen in liquid nitrogen prior to storage at −80 ◦C. 
2.2. Imaging 
For Nissl staining, standard procedures were used for the detection
of Nissl bodies found within neurons. Brieﬂy, brains were harvested
as described above and sectioned at 20 μm and placed on plus slides.
The slides were dried at 37 ◦C overnight, hydrated with distilled wa-
ter, 0.1% cresyl violet was applied for 7 min, and washed with distilled
water. The slides were then hydrated, cleared in xylene and cover-
slipped. Images were captured with a Nikon Eclipse TE2000-U ﬂuores-
cence microscope (Nikon Inc.). For immunoﬂuoroscence, Mice were
perfused with 4% paraformaldehyde and brains dissected and placed
in PFA overnight. Tissue was then transferred to glucose for 48 h.
Following cryosectioning, slices were permeabilized (0.1% Tween-20
in PBS, 5 min), and non-speciﬁc binding of antibodies was blocked
with PBS / 5.0% BSA for 1 h. Slices were probed with primary an-
tibodies and incubated overnight at 4 ◦C. The following antibodies
were used: (1:500, Neuron Signaling, Danvers, MA, USA): Anti-GFAP,
Anti-NeuN. After a washing step (PBS, 5 min), slices were counter-
stained with AlexaFluor-conjugated secondary antibodies (1:1000,
1 h, RT, PBS / 5% BSA; Molecular Probes, Eugene, OR, USA), washed
again and mounted onto slides with Prolong Gold Antifade reagent
containing DAPI (molecular probes). Stained slides were visualized
with a Nikon Eclipse TE2000-U ﬂuorescence microscope (Nikon Inc.).
For MRI, experiments were conducted at the Research Imaging Insti-
tute using a horizontal 7T Biospec system (BrukerBioSpin, Ettlingen,
Germany) and ParaVision 5 software. A small circular surface coil
(ID = 1.1 cm) was placed on top of the head. Mice were imaged un-
der 1.2% isoﬂurane with spontaneous breathing after placement in
a custom-made animal holder with ear and mouth bars. Respiration
rate (80–130 bpm) and rectal temperature (37 ± 0.5 ◦C) were contin-
uously monitored and maintained within normal physiological ranges
unless otherwise perturbed. High-resolution (isotropic 100 μm), T1-
weighted images were acquired using 3D FLASH sequence (scan pa-
rameters: with echo time (TE) 5.1 ms, repetition time (TR) 50 ms, ﬂip
angle of 30 ◦, ﬁeld of view (FOV) of 11 mm × 11 mm × 11 mm, matrix
12 T.M. Evans et al. / 3 (2014) 10–21 
Fig. 1. Imaging measures of mTBI. (A) Structural MRI of WT mouse brain 3 days post-TBI. Red square encompasses area of direct impact. N = 3. (B) Nissl stain (40 × magniﬁcation, 
line = 500 μm) of sham and TBI treated WT mouse cortex and hippocampus (Ca1 and Ca2 regions) 24 h post-TBI. N = 4. (C) DAPI (blue), NeuN (green) and GFAP (red) (20 ×
magniﬁcation, line = 100 μm) used to label nuclei, neurons and astrocytes in the ipsilateral (injured) cortex and hippocampus of sham and TBI animals 24 h post-TBI. N = 3. 
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Aize 1024 × 1024 × 1024). Preprocessing consisted of removing non- 
rain tissues and global spatial normalization. The GM and WM were 
eparated using FMRIB Software Library (FSL) packet (EPSRC, UK). 
he GM and WM volumes were determined using the Multi-Image 
nalysis GUI (MANGO) software ( http: // ric.uthscsa.edu / mango ). 2.3. Rotarod 
Neuromuscular function was tested using Rotamex 4 / 8 (Colum- 
bus Instruments, Columbus, OH). Each mouse was trained for ﬁve 
consecutive days (six trails / day) where the speed of the rotor was ac- 
celerated from 4 to 40 rpm with an acceleration of 0.2 rpm / s. Twenty- 
four hours after the last training session, the mice were tested in a 
T.M. Evans et al. / 3 (2014) 10–21 13 
Fig. 2. Body weight, apnea and righting reﬂex measures of mTBI (** p < 0.01, * p < 0.02). (A) mTBI causes a signiﬁcant reduction in body weight loss up to 7 days post-injury. 
(B) Time spent apneic following mTBI is signiﬁcantly increased as compared to sham controls. (C) Increased time to right self (righting reﬂex) following TBI is also signiﬁcantly 
increased. 
Fig. 3. Motor impairment measures of mTBI (* p < 0.05). (A) Signiﬁcantly reduced rotarod performance at 7 days, (B) 30 days, (C) 90 days post-injury ( p < 0.05) and (D) grip 
strength was decreased at 2 days post-injury and signiﬁcantly reduced at 7 days post-injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 probe trial consisting of six trials as previously described. The latency
to fall was then recorded. 
2.4. Grip strength 
Forelimb muscle strength was determined by measuring peak
force (in pounds) using the Digital Grip Strength meter equipped
with a Hind Limb Pull Bar Assembly (Columbus Instruments, Colum-
bus, OH). Mice are allowed to grip the metal grids of a grip meter
with their forepaws, and gently pulled backwards by the tail until
they could no longer hold the grids. The peak grip force observed in
10 trials was recorded [ 24 ]. 
2.5. Electromyography 
Bilateral hind limb muscle groups were examined with a Nico-
let, Viking Quest portable EMG apparatus (CareFusion San Diego, CA,
USA). A monopolar electrode (active) was inserted into the muscleof interest. An identical electrode (reference) was inserted subcu-
taneously into the lateral and distal-most tendinous portion of the
gastroc-soleus complex, ipsilateral to the muscle studied. A subder-
mal needle (ground) was inserted subcutaneously into tendinous tis-
sue posterior to and near the reference electrode. Abnormal sponta-
neous activity in the form of denervation potentials (positive sharp
waves and ﬁbrillations) was recorded using an electromyography ab-
normality score scale ( Fig. 5 A). 
2.6. Isoprostanes 
F 2 -isoprostanes and F 4 -neuroprostanes were measured in ipsilat-
eral brain using the gas chromatography–mass spectrometry method
of Morrow and Roberts [ 25 ]. Tissue was collected and homogenized
in chloroform:methanol containing 0.005% butylatedhydroxytoluene
(BHT) to prevent auto-oxidation, dried under a stream of nitrogen, and
re-suspended in methanol containing BHT. Esteriﬁed F 2 -isoprostanes
in phospholipids were saponiﬁed, to free fatty acids from lipids, by
14 T.M. Evans et al. / 3 (2014) 10–21 
Fig. 4. Motor unit integrity measures of mTBI (** p < 0.01). (A) Representative tracings of electromyography abnormality scoring used in the current study. (B) Electromyography 
of hind limb muscles indicates signiﬁcant abnormality in the form of denervation potentials at all time points tested post-injury. (C) Changes in muscle mass at 4 months 
post-injury. (D) Muscle mass normalized to body weight. 
Fig. 5. Isoprostane measures of mTBI (**** p < 0.0001, ** p < 0.001). Signiﬁcantly increased A: F2-isoprostanes and B: F4-isoprostanes 48 h following mTBI as compared to sham. 
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rdding aqueous potassium hydroxide. Then, the sample was acidi- 
ed and diluted with water. Next, deuterated-F 2 -isoprostane inter- 
al standard was added to the mixture. For the measurement of free 
 2- isoprotanes / F 2 -isofuranes in plasma, the extraction and hydroly- 
is steps were omitted, and the sample was simply acidiﬁed, diluted, 
nd the internal standard added. The mixture was subsequently run 
n a silica column to separate isoprostanes / isofuranes from bulk fatty 
cids. The eluate was converted to pentaﬂuorobenzyl esters, by treat- 
ent with pentaﬂuorobenzyl bromide to improve separation efﬁ- 
iency. The mixture was then subjected to thin layer chromatogra- 
hy to remove the excess pentaﬂuorobenzyl bromide and unreacted 
atty acids. The F 2 -isoprotane / isofurane fraction was extracted us- 
ng ethyl acetate, and analyzed. F 2 -isoprostanes were quantiﬁed by 
eak height, the data were corrected with the internal standard, and 
esults were calculated as nanogram of F 2 -isoprostanes per mL of plasma or per gram tissue. F 4 -neuroprostanes, a lipid peroxidation 
product of docosahexaenoic acid was also determined some modi- 
ﬁcations of the F 2 -isoprostane method. Brieﬂy, 100–200 mg tissue 
was homogenized in ice-cold Folch solution containing BHT. Lipids 
were then extracted and chemically hydrolyzed with 15% KOH. After 
acidiﬁcation with HCl and addition of a stable isotope-labeled in- 
ternal standard, 8-iso-prostaglandin F 2 α-d 4 , F 4 -neuroprostanes were 
applied to a C18 Sep-Pak cartridge and a silica Sep-Pak column for fur- 
ther puriﬁcation. Unlike the F 2 -isoprostane assay, the washing step 
for silica columns used an ethyl acetate / heptane (75:25) mixture in- 
stead of pure ethyl acetate because of the polarity difference between 
F 2 -isoprostanes and F 4 -neuroprostanes. The eluted compounds are 
dried under N 2 , converted to pentaﬂuorobenzyl esters, and puriﬁed 
by thin-layer chromatography. Instead of a 1.5 cm narrow cut for iso- 
prostane measurement, the scraped area was extended to 4 cm above 
T.M. Evans et al. / 3 (2014) 10–21 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 and 1 cm below the PGF 2 a methyl ester migration. The puriﬁed F 4 -
neuroprostanes were derivatized to trimethysilyl ether derivatives
then dissolved in undecane that was dried over a bed of calcium
hydride. Negative ion chemical ionization MS was performed by Ag-
ilent 6890 GC and Model 5975 MSD instruments with selected ions
monitored for [ 2 H 4 ]15-F 2 α-IsoP internal standard ( m / z 573) and F 4 -
NeuroPs ( m / z 593). 
2.7. Sham control vs. mTBI mouse specimens 
Cryropreserved ipsilateral C57Bl6 mouse brain specimens were
obtained at various post-injury time points following closed skull
mTBI. All mice used were 60 days of age at the time of primary brain
injury. 
2.8. Microwave and magnetic (M2) sample preparation 
Protein was pooled from all specimens by protein amount as refer-
ence material. For isobaric TMT labeling, 50 mg of C8 magnetic beads
(BcMg, Bioclone Inc.) were suspended in 1 mL of 50% methanol. Im-
mediately before use, 100 μL of the beads were washed 3 times with
equilibration buffer (200 mM NaCl, 0.1% triﬂuoroacetic acid (TFA)).
Whole cell protein lysate (25–100 μg at 1 μg / μL) was mixed with
pre-equilibrated beads and 1 / 3rd sample binding buffer (800 mM
NaCl, 0.4% TFA) by volume. The mixture was incubated at room tem-
perature for 5 min followed by removing the supernatant. The beads
were washed twice with 150 μL of 40 mM triethylammonium bi-
carbonate (TEAB), and then 150 μL of 10 mM dithiolthreitol (DTT)
was added. The bead-lysate mixture underwent microwave heating
for 10 s. DTT was removed and 150 μL of 50 mM iodoacetamide
(IAA) added, followed by a second microwave heating for 10 s. The
beads were washed twice and re-suspended in 150 μL of 40 mM
TEAB. In vitro proteolysis was performed with 4 μL of trypsin in a
1:25 trypsin-to-protein ratio (stock = 1 μg / μL in 50 mM acetic acid)
with microwave-assisted heating for 20 s in triplicate. The super-
natant was used immediately or stored at −80 ◦C. Released tryptic
peptides from digested protein lysates, including the reference mate-
rials described above, were modiﬁed at the N-terminus and at lysine
residues with the tandem mass tagging (TMT)-6plex isobaric labeling
reagents (Thermo scientiﬁc, San Jose, CA). Each individual specimen
was encoded with one of the TMT-126-130 reagents, while reference
material was encoded with the TMT-131 reagent: 41 μL of anhy-
drous acetonitrile was added to 0.8 mg of TMT labeling reagent for
25 μg of protein lysate and microwave-heated for 10 s. To quench
the reaction, 8 μL of 5% hydroxylamine was added to the sample at
room temperature. To normalize across all specimens, TMT-encoded
cell lysates from individual specimens, labeled with the TMT-126-130
reagents, were mixed with the reference material encoded with the
TMT-131 reagent in 1 126 :1 127 :1 128 :1 129 :1 130 :1 131 ratios. These sam-
ple mixtures, including all TMT-encoded specimens, were stored at
−80 ◦C until further use. 
2.9. Capillary liquid chromatography-fourier-transform-tandem mass 
spectrometry (LC / FT / MS / MS) with protein database searching 
Capillary LC / FT / MS / MS was performed with a splitless nanoLC-
2D pump (Eksigent, Livermore, CA), a 50 μm-i.d. column packed with
7 cm of 3 μm-o.d. C18 particles, and a hybrid linear ion trap-Fourier-
transform tandem mass spectrometer (LTQ-ELITE; Thermo, Fisher,
San Jose, CA) operated with a lock mass for calibration. The reverse-
phase gradient was 2–62% of 0.1% formic acid (FA) in acetonitrile over
60 min at 350 nL / min. For unbiased analyses, the top six most abun-
dant eluting ions were fragmented by data-dependent HCD with a
mass resolution of 120,000 for MS and 15,000 for MS / MS. For iso-
baric TMT labeling, probability-based protein database searching of
MS / MS spectra against the Trembl mouse protein database (release2012 dec29; 59,862 sequences) was performed with a 10-node MAS-
COT cluster (v. 2 / 3 / 02, Matrix Science, London, UK) with the follow-
ing search criteria: peak picking with Mascot Distiller; 10 ppm pre-
cursor ion mass tolerance, 0.8 Da product ion mass tolerance, three
missed cleavages, trypsin, carbamidomethyl cysteines as a static mod-
iﬁcation, oxidized methionines and deamidated asparagines as vari-
able modiﬁcations, an ion score threshold of 20 and TMT-6-plex for
quantiﬁcation. 
2.10. Western blot 
Western blot analysis was performed on lysates from ipsilateral
brain samples in order to conﬁrm our proteomics results. Equiva-
lent amounts of protein from each sample were subjected to sodium
dodecyl sulfate-polyacrylamide electrophoresis using 4–12% Bis–Tris
precast gels (Invitrogen, CA, USA) under reducing and non reducing
conditions (1 h, RT) and electroblotted onto a nitrocellulose mem-
brane (18 h, overnight, Bio Rad). Following a blocking step (0.1%
Tween-20 / 5% nonfat milk in PBS, 1 h, RT) membranes were incu-
bated with primary antibodies overnight (12–14 h, 4 ◦C) with gentle
agitation. The following primary antibodies were used (1:1000): Anti-
MBP (Millipore), Anti-MAG (AbCam), Anti-Beta Actin (Cell Signaling).
Membranes were washed, incubated with secondary antibody (RT,
1 h, Cell Signaling) and developed with SuperSignal West Dura Ex-
tended Duration Substrate (Thermo Scientiﬁc). 
2.11. Statistical analysis 
M 2 proteomics technical replicates estimated protein expression
for individual specimens, TMT-encoded in sample mixtures, relative
to pooled reference materials. Relative protein expression levels were
transformed to log base 2 for quantile normalization. We tested the
association between relative protein expression with rotarod, grip
strength and motor unit integrity measures (EMG) using linear regres-
sion or ANOVA. All statistical analyses were performed with Graph-
Pad Prism software (GraphPad Software Inc.) or R v3.0 + (R Project,
Vienna, Austria). 
3. Results 
3.1. Imaging measures of mTBI 
Anatomical images of the mouse brain after mTBI, obtained with
7T MRI show no signs of herniation, midline shift, overt edema or
hemorrhaging ( Fig. 1 A), consistent with the clinical diagnosis of mTBI
and supporting our closed-skull mTBI mouse model. For analysis of
cell loss and edema in brain cryosections, the mice were perfused
48 hours post-TBI, and brains from wild-type sham and TBI mice were
collected and cryosectioned. Sections were stained with Nissl in order
to visualize edema ( Fig. 1 B). Staining was more diffuse in the brains
of TBI animals with visible decreases in cell number and increases in
cellular size (edema). Immunoﬂourescence double-labeling for neu-
rons and astrocytes indicates a loss of neurons (NeuN, Green) in the
cortex and hippocampus under the site of injury and an increase in
astrogliosis as indicated by increases in GFAP (red) 24 h following
injury ( Fig. 1 C). 
3.2. Body weight, apnea and righting reﬂex measures of mTBI 
Following mTBI, animals experienced a signiﬁcant loss of body
weight at 1 and 2 days post TBI that returned to non-signiﬁcant levels
by 7 days post-injury ( p = 0.01, Fig. 2 A). After mTBI, mice experienced
an apneic episode averaging 45 s, signiﬁcantly higher than sham con-
trols ( p = 0.02, Fig. 2B ). Animals also experienced a signiﬁcant increase
righting reﬂex following recovery from anesthesia when compared to
sham controls ( Fig. 2C , p = 0.02). 
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Fig. 6. M 2 proteomics measures of mTBI (*** p < 0.001, ** p < 0.05). (A) Signiﬁcantly decreased MBP expression up to 30 days post-injury as compared to sham controls at 180 days 
of age. (B) Signiﬁcantly increased MAG expression up to 30 days post-injury. Western blots of (C) MBP (18–23 kDa) and (D) MAG (63 kDa) with beta-actin (45 kDa) as a loading 
control were used to conﬁrm M 2 proteomics results. 
Table 1 
Top-ranked associations for relative protein expression correlated to post-injury time (vs. sham controls). The post-injury time point (vs. sham), log 2 fold change in protein 
expression (vs. sham), p -value for post-injury time point (vs. sham), overall p -value for all time-points (vs. sham), Trembl protein symbol, and protein description are shown with 
examples in bold and italics. 
Post-injury time 
point (vs. sham) 
Log 2 fold change in 
protein expression 
(vs. sham) 
p -value for post-injury 
time point (vs. sham) 
Overall p -value for all 
time-points (vs. sham) 
Trembl protein 
symbol Protein description 
Day30 −0 .7162 0 .0004 0 .0007 F6RT34 MOUSE Myelin basic protein (Fragment) OS = Mus musculus GN = Mbp PE = 4SV = 1 
Day7 −0 .7605 0 .0007 0 .0007 F6RT34 MOUSE Myelin basic protein (Fragment) OS = Mus musculus GN = Mbp PE = 4SV = 1 
Day1 −0 .6614 0 .0011 0 .0007 F6RT34 MOUSE Myelin basic protein (Fragment) OS = Mus musculus GN = Mbp PE = 4SV = 1 
Day7 −0 .3883 0 .0095 0 .0712 D5MR34 MOUSE Tubulin beta 3 (Fragment) OS = Mus musculus GN = Tubb3 PE = 3SV = 1 
Day7 −0 .6319 0 .0098 0 .0690 Q8R1B2 MOUSE Actr1b protein (Fragment) OS = Mus musculus GN = Actr1b PE = 2SV = 1 
Day7 0 .3705 0 .0117 0 .0450 Q3T1F6 MOUSE Myelin-associated glycoprotein OS = Mus musculus GN = Mag PE = 2SV = 1 
Day7 −0 .2128 0 .0122 0 .0779 E9PVM7 MOUSE Glutathione S-transferase Mu 5 (Fragment) OS = Mus musculus GN = Gstm5 PE = 3SV = 1 
Day120 0 .4588 0 .0141 0 .0602 B2RTM0 MOUSE Histone H4 OS = Mus musculus GN = Gm11275 PE = 3SV = 1 
Day7 −0 .3137 0 .0166 0 .0652 Q80ZV2 MOUSE Tubb5 protein (Fragment) OS = Mus musculus GN = Tubb5 PE = 2SV = 1 
Day30 0 .3310 0 .0205 0 .0450 Q3T1F6 MOUSE Myelin-associated glycoprotein OS = Mus musculus GN = Mag PE = 2SV = 1 
Day1 −0 .1867 0 .0231 0 .0779 E9PVM7 MOUSE Glutathione S-transferase Mu 5 (Fragment) OS = Mus musculus GN = Gstm5 PE = 3SV = 1 
Day7 −0 .3895 0 .0273 0 .1359 B1AQZ2 MOUSE Kinesin family member 3A OS = Mus musculus GN = Kif3a PE = 3SV = 1 
Day7 0 .3047 0 .0296 0 .2298 Q3TJH1 MOUSE Putative uncharacterized protein OS = Mus musculus GN = Gnai3 PE = 2SV = 1 
Day1 0 .3050 0 .0297 0 .0450 Q3T1F6 MOUSE Myelin-associated glycoprotein OS = Mus musculus GN = Mag PE = 2SV = 1 
Day30 −0 .1733 0 .0322 0 .0779 E9PVM7 MOUSE Glutathione S-transferase Mu 5 (Fragment) OS = Mus musculus GN = Gstm5 PE = 3SV = 1 
Day120 −0 .2409 0 .0322 0 .2271 E9Q0U7 MOUSE Heat shock protein 105 kDa OS = Mus musculus GN = Hsph1 PE = 3SV = 1 
Day30 −0 .4112 0 .0346 0 .2477 Q3UMG4 MOUSE Putative uncharacterized protein (Fragment) OS = Mus musculus GN = Ina, PE = 2SV = 1 
Day7 −0 .4627 0 .0382 0 .1140 Q3ULW0 MOUSE Putative uncharacterized protein OS = Mus musculus GN = Ran PE = 2SV = 1 
Day30 0 .6178 0 .0528 0 .3263 Q9Z1R9 MOUSE MCG124046 OS = Mus musculus GN = Prss1 PE = 2SV = 1 
Day7 0 .3261 0 .0539 0 .2529 D3Z2Y8 MOUSE D-beta-hydroxybutyrate dehydrogenase, mitochondrial (Fragment) OS = Mus musculus 
GN = Bdh1 PE = 3SV = 1 
Day1 −0 .2217 0 .0587 0 .2989 Q3TWL6 MOUSE Putative uncharacterized protein OS = Mus musculus GN = Psmd2 PE = 2SV = 1 
Day7 −0 .3719 0 .0592 0 .2837 Q05DD2 MOUSE Neﬂ protein (Fragment) OS = Mus musculus GN = Neﬂ PE = 2SV = 1 
Day120 −0 .4108 0 .0601 0 .1140 Q3ULW0 MOUSE Putative uncharacterized protein OS = Mus musculus GN = Ran PE = 2SV = 1 
Day30 0 .2755 0 .0607 0 .1185 A4FUS1 MOUSE MCG123443 OS = Mus musculus GN = Rps16 PE = 2SV = 1 
Day1 0 .2431 0 .0616 0 .2378 H3BK84 MOUSE cAMP-dependent protein kinase type II-beta regulatory subunit OS = Mus musculus 
GN = Prkar2b PE = 4SV = 1 
Day120 0 .2345 0 .0621 0 .3348 Q3TIU7 MOUSE Putative uncharacterized protein OS = Mus musculus GN = Ndufs1 PE = 2SV = 1 
Day1 −0 .6893 0 .0646 0 .3239 Q3UJ20 MOUSE Putative uncharacterized protein OS = Mus musculus GN = Eno2 PE = 2SV = 1 
Day120 −0 .5581 0 .0666 0 .2934 F6SAC3 MOUSE Glucose-6-phosphate isomerase (Fragment) OS = Mus musculus GN = Gm1840 PE = 3SV = 1 
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Fig. 7. A representative MS / MS spectrum for MBP121-132 (TQDENPVVHFFK). This 
spectrum shows the probability-based protein database search assignment of 19 / 
23 amino acid sequence-speciﬁc b- and y-type ions (expectation = 5.8E −7), with a 
zoomed-in view of the TMT126-131 reporter ions used for quantiﬁcation of this pep- 
tide in specimens from individual mice (inset). The post-injury time point (0, 1, 7, 30 
and 120 days) for each reporter ion is also shown, where ref = the pooled reference 
used to normalize relative expression across all specimens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.3. Motor impairment measures of mTBI 
As indicated in Fig. 3 A and 3B, mTBI is capable of initiating a sig-
niﬁcant decrease in rotarod performance in WT mice at 7 and 30 days
post-injury (mTBI vs. sham, p = 0.05) but not at 90 days post-injury,
Fig. 3 C. TBI animals had a trend toward lower maximum grip strength
at 2 days post-injury ( p = 0.06), which became signiﬁcant by 7 days
post-injury ( p = 0.05) as compared to sham controls ( Fig. 3 D). 
3.4. Motor unit integrity measures of mTBI 
Further, there is a marked increase in EMG abnormalities in mTBI
mice as early as 7 days post-injury (two way ANOVA, p = 0.001, Fig.
4 B). These signiﬁcant abnormalities in motor unit integrity persist up
to 120 months after mTBI. EMG abnormalities are not accompanied
by loss of muscle mass as shown in Fig. 4 C. 
3.5. Isoprostane measures of mTBI 
We sought to determine if our closed-skull mTBI mouse model
(primary injury) led to increases in oxidative stress. To address this
question, we examined levels of F2-isoprostanes ( Fig. 5 A) and F4-
Neuorprostanes ( Fig. 5 B) following mTBI. Our results are consis-
tent with the literature: we observed signiﬁcant increases in F2-
isoprostances and F4-neuroprostanes in the ipsilateral cortex 48 h
post-injury mTBI ( p = 0.0001) that returned to sham levels by 7 days
post-injury, supporting our closed-skull mTBI mouse model. 
3.6. M 2 proteomics of mTBI 
Decoding the relative expression of 476 ± 56 top-ranked pro-
teins for each specimen revealed statistically signiﬁcant changes in
the expression of two well-known CSPs at 1, 7 and 30 days post-
injury: p < 0.001 for myelin basic protein (MBP) and p < 0.05 for
myelin associated glycoprotein (MAG) ( Fig. 6 A and B, and Supple-
mentary Table 1). This was conﬁrmed with Western blotting ( Fig.
6 C). MBP and MAG protein expression was inferred from the fol-
lowing top-scoring TMT-labeled tryptic peptides generated in vitro
as part of our M 2 proteomics procedure: MBP50-59 (DTGILDSIGR);
MBP60-65 (FFSGDR); MBP121-132 (TQDENPVVHFFK); and MBP155-
171 (FSWGAEGQKPGFGYGGRASDYK). Likewise, the following top-
scoring TMT-labeled peptides from MAG were quantiﬁed: MAG78-90
(TQVVHESFQGRSR) and MAG189-208 (LREDEGTWVQVSLLHFVPTR). A
representative MS / MS spectrum for MBP121-132 (TQDENPVVHFFK)
shows the probability-based protein database search assignment of19 / 23 amino acid sequence-speciﬁc b- and y-type ions (expecta-
tion = 5.8E −7), with a zoomed-in view of the TMT126-131 reporter
ions used for quantiﬁcation of this peptide in specimens from indi-
vidual mice (inset) ( Fig. 7 ). The post-injury time point (0, 1, 7, 30 and
120 days) for each reporter ion is also shown, where ref = the pooled
reference used to normalize relative expression across all specimens.
The trajectory of MBP121-132 expression is evident in the trajectory
inferred for MBP expression ( Fig. 6A ). Other differentially expressed
proteins, including other well-known CSPs, were also revealed by
M 2 proteomics. For example, decreased expression of αII-spectrin
(SPNA2) and neuroﬁlament light (NEFL) were directly correlated to
decreased grip strength ( p < 0. 05) ( Fig. 8 and Supplementary Table
2). The majority of the remaining proteins did not exhibit statistically
signiﬁcant correlations to post-injury time and / or grip strength, as
expected. However, some of these proteins are known to be important
to TBI, including: glutathione S-transferase μ (GSTM5) and glucose-
6-phosphate isomerase (GPI) (see Table 1 showing top-ranked corre-
lations from Supplementary Table 1). 
4. Discussion 
The goal of the current study was to investigate whether changes
in CSP expression correlate to long-term secondary effects on mo-
tor unit impairment and integrity, as well as to investigate potential
underlying molecular mechanisms for these lasting effects, with M 2
proteomics. Our imaging and isoprostane measures were consistent
with the clinical diagnosis of mild TBI (mTBI) and are support for our
closed-skull mTBI mouse model. Decoding the relative protein ex-
pression for each specimen revealed statistically signiﬁcant changes
in the expression of the CSPs known as MBP and MAG. MBP expression
was rapidly reduced, by 24 h, in the ipsilateral brain following mTBI
and was signiﬁcantly down-regulated for up to 30 days post-injury.
Decreased MBP expression was mirrored by increased MAG expres-
sion during the same time period. Moreover, increased grip strength
revealed that increased MAG expression was directly related to motor
impairment at 30 days post-injury (Supplementary Table 2). A brief
discussion of previous work on MBP, MAG and other CSP biomarkers
of mTBI are provided below. 
MBP is the second most abundant protein in CNS myelin, com-
prising ˜ 30% of the total protein in the myelin sheath [ 26 –28 ]. It is a
positively charged membrane bound protein that binds to negatively
charged lipids, present at the cytosolic surface of myelin, and alterna-
tive splicing and post-translational modiﬁcations generate numerous
isoforms [ 26 , 29 –34 ]. MBP has most often been associated with pedi-
atric mTBI [ 35 –37 ]. For example, an increase in MBP levels in the CSF
was observed in a small sample of 14 pediatric mTBI patients [ 38 ].
It is also believed to be a potential biomarker of traumatic axonal
injury (TAI) [ 39 ]. TAI represents a mechanism of secondary (long-
term) injury, resulting from increased oxidative stress due to calcium
accumulation and mitochondrial failure in injured axons [ 40 –42 ]. In-
creases in CSF levels of MBP have been seen in multiple models of
mTBI also, including pediatric TBI and blast-induced TBI [ 28 , 35 ]. MBP
is cytotoxic and promotes inﬂammation by activating the release of
histamine and it is present at extracellular sites of pathological ﬁbrotic
lesions in several disease models [ 43 , 44 ]. Therefore, the transport of
MBP across the blood–brain-barrier and into the periphery could be
contributing to the motor impairment observed in this animal model
of mTBI. 
MAG is a member of the immunoglobulin-like family and provides
a source of inhibition for growing neuritis after CNS injury [ 45 , 46 ].
Most of the current studies on injury-induced growth inhibition have
been performed in spinal cord injury. Few studies have investigated
the role of MAG in the pathogenesis of mTBI [ 46 –49 ]. Intriguingly, a
rodent model of ﬂuid percussion injury has been employed to show
that treatment with an anti-MAG monoclonal antibody can improve
neurologic motor, sensory and cognitive function for up to 8 weeks
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Fig. 8. M 2 proteomics measures of mTBI correlated to grip strength (* p < 0.05). Decreased expression of (A) SPNA2 and (B) NEFL directly correlated to decreased grip strength at 
30 days post-injury, as shown in (C) and (D), respectively. 
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aost-injury [ 49 ]. Likewise, central and systemic administration of 
nti-MAG antibody signiﬁcantly reduced lesion volume, improved 
otor function and reduced oxidative stress responses in a rat model 
f middle cerebral artery occlusion [ 50 ]. These studies support the 
nvolvement of MAG in CNS injury pathology as well as its use as a 
otential therapeutic target for future studies. 
We also observed that MAG, SPNA2 and NEFL expressions at 
0 days post-injury were directly correlated to grip strength ( p 
 0.05) ( Fig. 8 and Supplementary Table 2). Breakdown products (i.e., 
leavage or proteolytic processing) of the cytoskeletal protein SPNA2 
e.g., SBDP145) that is abundant in axons and pre-synaptic terminals 
f neurons are generated by calcium-dependent cysteine protease(s) 
e.g., calpains and caspases) during necrosis (and / or apoptosis) fol- 
owing TBI [ 51 , 52 ]. The nominal mass of the MBP isoform measured 
y M 2 proteomics herein is 23,197 Da, while an 18 kDa isoform was 
he most abundant band measured with Western blotting ( Fig. 6A 
nd C ). However, since M 2 proteomics did not achieve 100% sequence coverage (i.e., the C-terminus is missing) for this (or any other CSP) 
and the antibody employed was not isoform-speciﬁc, we cannot un- 
ambiguously assign our results solely to this isoform or its breakdown 
products [ 53 ]. 
Neuroﬁlament proteins are major cytoskeletal structural proteins 
of neurons and are found heavily concentrated in axons [ 54 –56 ]. NEFL 
shows some promise as an indicator of acute axonal damage [ 57 ]. Un- 
fortunately, NEFL is degraded relatively rapidly in the CSF or blood, 
thus potentially confounding NEFL measurements [ 58 ]. While our 
data on linking MAG, SPNA2 and NEFL expression to grip strength are 
preliminary, epidemiological data suggest signiﬁcant correlations of 
TBI to the development of CNS pathologies with long-term motor dys- 
function, including; amyotrophic lateral sclerosis (ALS), Parkinson ’ s 
disease, Alzheimer ’ s disease and chronic traumatic encephalopathy 
[ 10 –13 ]. For example, TBI has been linked to a ˜ 3-fold increased risk 
of ALS [ 13 , 59 ], and the genes and environmental exposures in vet- 
erans with ALS (GENEVA) case-control study revealed signiﬁcantly 
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 increased risk of ALS in veterans with a TBI [ 12 ]. 
Lastly, we brieﬂy discuss two of the proteins shown in Table 1
that did not exhibit statistically signiﬁcant correlations to post-injury
time and / or grip strength: GSTM5 and GPI. GSTM5 is a member of
the glutathione s-transferase superfamily: a major group of detoxi-
ﬁcation enzymes that alleviates the damage from lipid peroxidation
by-products (e.g., 4-HNE and acrolein) by catalyzing their conjugation
with glutathione [ 60 , 61 ]. Our results indicate increased lipid peroxi-
dation during mTBI, which could be exacerbated by decreased levels
of GSTM5 [ 62 ]. GPI is a dimeric enzyme that catalyzes the reversible
isomerization of glucose-6-phosphate and fructose-6-phosphate. In
the cytoplasm, GPI is involved in glycolysis and gluconeogenesis,
while outside the cell it functions as a neurotrophic factor for spinal
and sensory neurons. Interestingly, we also observed that GPI levels
were decreased in mTBI vs. sham. In contrast, we observed increased
levels of GPI in our previous work on a mouse model of multiple
sclerosis [ 22 ]. 
4.1. Signiﬁcance of M 2 proteomics 
M 2 proteomics was developed to provide the following advan-
tages: to improve sample throughput by decreasing lengthy sample
preparation times, to improve sensitivity by decreasing adsorptive
losses, and to improve statistical power by enabling quantitative MS /
MS-based proteomic studies with relatively large numbers of spec-
imens. One disadvantage is the greater computational burden that
comes with larger numbers of specimens and MS / MS spectra. A rig-
orous comparison of the analytical ﬁgures of merit for M 2 proteomics
vs. other proteomics methods is beyond the scope of this work, in-
cluding: M 2 proteomics vs. conventional approaches for quantitative
MS / MS-based proteomics, bead-based immunoassays, and gel-based
proteomic methods such as two-dimensional electrophoresis. How-
ever, since our initial publications on M 2 proteomics [ 22 , 23 ], we have
successfully applied M 2 proteomics to a variety of preclinical and
clinical studies. Moreover, there is a growing number of reports of
high-throughput sample preparation by microwave-assisted diges-
tion [ 63 , 64 ] or by magnetic beads [ 65 ], high-sensitivity on-bead di-
gestions [ 66 ], and isobaric labeling reagents for multiplexed protein
quantiﬁcation by MS / MS-based proteomics [ 67 , 68 ]. 
5. Conclusions 
While higher-powered studies of larger cohorts merit further in-
vestigation, this study supports the proof-of-concept that M 2 pro-
teomics is a rapid method to quantify putative CSP biomarkers and
therapeutic targets of mTBI and suggests the feasibility of correlations
to long-term effects on motor impairment. Based on our own results
and previous work, we posit that a decrease in MBP expression and /
or an increase in MAG expression might contribute to impaired motor
function and neuronal regeneration in mTBI patients. From these pre-
liminary studies, we also hypothesize that M 2 proteomics can reveal
subtler changes in CSP expression than those observed herein, such
as those reﬂecting long-term secondary effects on motor impairment
and unit integrity, as well as underlying molecular mechanisms, at
180 days post-injury and beyond. For these reasons and others, M 2
proteomics is expected to become increasingly important to accu-
rately predict clinical outcome and improve risk group stratiﬁcation
and therapy for mTBI patients. 
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